Artal Group S.A. Verastem, Inc. Transaction History

Artal Group S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 10, 2018	SELL	$2.92 - $3.81 $2.92 Million - $3.81 Million	-1,000,000 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$2.99 - $4.85 $747,500 - $1.21 Million	250,000 Added 33.33%	1,000,000 $3.07 Million
Q3 2017 Nov 08, 2017	BUY	$3.01 - $5.41 $2.26 Million - $4.06 Million	750,000	750,000 $3.53 Million

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $895M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.